1. Cell Cycle/DNA Damage
    Epigenetics
  2. Aurora Kinase

Aurora Kinase

Aurora kinases are serine/threonine kinases that are essential for cell proliferation. Aurora kinase helps the dividing cell dispense its genetic materials to its daughter cells. More specifically, Aurora kinases play a crucial role in cellular division by controlling chromatid segregation. Defects in this segregation can cause genetic instability, a condition which is highly associated with tumorigenesis. Three Aurora kinases have been identified in mammalian cells to date, Aurora A, Aurora B, Aurora C. Besides being implicated as mitotic regulators, these three kinases have generated significant interest in the cancer research field due to their elevated expression profiles in many human cancers. The human Aurora kinases present a similar domain organization, with a N-terminal domain of 39 to 129 residues in length, a protein kinase domain and a short C-terminal domain containing 15 to 20 residues. The N-terminal domain of three proteins share low sequence conservation, which determines selectivity during protein-protein interactions.

Aurora Kinase Related Products (32):

Cat. No. Product Name Effect Purity
  • HY-10971
    Alisertib Inhibitor 99.43%
    Alisertib (MLN 8237) is a selective Aurora A inhibitor with IC50 of 1.2 nM, and is more selective for Aurora A than Aurora B.
  • HY-10161
    Tozasertib Inhibitor 99.77%
    Tozasertib is the inhibitor of Aurora-A, -B, -C kinases with Ki values of 0.6, 18, 4.6 nM, respectively.
  • HY-50514
    AT9283 Inhibitor 99.13%
    AT9283 is a multi-targeted inhibitor with IC50s of 1.2 nM, 1.1 nM for JAK2 and JAK3, respectively, and is also potent to Aurora A, Aurora B and Abl(T315I).
  • HY-10126
    AZD1152-HQPA Inhibitor 99.64%
    AZD1152-HQPA is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay, and appr 3700 fold more selective for Aurora B over Aurora A.
  • HY-10180
    MLN8054 Inhibitor >98.0%
    MLN8054 is a potent, selective and orally available aurora A kinase inhibitor with an IC50 of 4 nM.
  • HY-10179
    Danusertib Inhibitor 99.44%
    Danusertib is a pyrrolo-pyrazole and aurora kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.
  • HY-13253
    AMG 900 Inhibitor 99.30%
    AMG 900 is a potent and highly selective pan-Aurora kinases inhibitor with IC50 of 5 nM, 4 nM and 1 nM for Aurora A, B and C, respectively.
  • HY-14711
    Reversine Inhibitor 99.25%
    Reversine is a novel class of ATP-competitive Aurora kinase inhibitor with IC50s of 400, 500 and 400 nM for Aurora A, Aurora B and Aurora C, respectively.
  • HY-13252
    MK-5108 Inhibitor >98.0%
    MK-5108 is a highly potent and specific inhibitor of Aurora-A kinase with an IC50 value of 0.064 nM.
  • HY-10127
    AZD1152 Inhibitor
    AZD1152 is a pro-drug of Barasertib-hQPA, which is a highly selective Aurora B inhibitor with IC50 of 0.37 nM in a cell-free assay.
  • HY-12054
    Hesperadin Inhibitor 99.67%
    Hesperadin is an ATP-competitive inhibitor of aurora B kinase with an IC50 of 250 nM.
  • HY-10128
    ZM-447439 Inhibitor 98.88%
    ZM-447439 is an aurora kinase inhibitor with IC50s of 110 and 130 nM for aurora A and B, respectively.
  • HY-70044
    GSK-1070916 Inhibitor 99.55%
    GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A.
  • HY-10329
    JNJ-7706621 Inhibitor 99.82%
    JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9, 3, 11, and 15 nM for CDK1, CDK2, Aurora-A and Aurora-B, respectively.
  • HY-14574
    PF-03814735 Inhibitor 99.24%
    PF-03814735 is a potent, orally available and reversible aurora A and aurora B inhibitor with IC50s of 0.8 and 0.5 nM, respectively.
  • HY-10339
    KW-2449 Inhibitor 99.85%
    KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABLT315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively.
  • HY-12201
    TAK-901 Inhibitor 99.80%
    TAK-901 is a multi-targeted aurora inhibitor with IC50s of 21 and 15 nM for aurora A and B, respectively.
  • HY-10804
    CCT 137690 Inhibitor 98.33%
    CCT 137690 is a potent and orally available aurora kinase inhibitor with IC50s of 15, 25, and 19 nM for aurora A, B and C, respectively.
  • HY-12049
    CCT129202 Inhibitor
    CCT 137690 is an aurora kinase inhibitor with IC50s of 42, 198, and 227 nM for aurora A, B and C, respectively.
  • HY-15767
    TAK-632 Inhibitor 98.87%
    TAK-632 is a potent pan-RAF inhibitor with IC50 of 1.4, 2.4 and 8.3 nM for CRAF, BRAFV600E, BRAFWT, respectively.